Phathom Pharmaceuticals, Inc. SG&A Expenses

SG&A Expenses of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative

Highlights and Quick Summary

  • SG&A Expenses for the quarter ending September 29, 2021 was $16.4 Million (a 20.66% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 53.23%
  • Annual SG&A Expenses for 2020 was $27.2 Million (a 292.4% increase from previous year)
  • Annual SG&A Expenses for 2019 was $6.94 Million (a 475.6% increase from previous year)
  • Twelve month SG&A Expenses ending September 29, 2021 was $53.6 Million (a 21.36% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 95.9% year-over-year
Trailing SG&A Expenses for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$53.6 Million $44.1 Million $35.7 Million $27.3 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Phathom Pharmaceuticals, Inc.

Most recent SG&A Expensesof PHAT including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $16.4 $13.59 $12.88
2020 $10.7 $6.97 $5.16 $4.51 $27.22
2019 $2.99 $1.81 $1.35 $0.8 $6.94
2018 $0.26 $1.21

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.